SCHEMBL19928107

SCHEMBL19928107

CC(C)(C)c1ccc2ncn(C3CNC3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 3/20 0.48
IDO1 P14902 5/20 0.38
CHRNB2 P17787 3/20 0.37
CHRNA4 P43681 3/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
IKZF3 Q9UKT9 1/20 0.34
KCNH2 Q12809 2/20 0.34
DRD2 P14416 1/20 0.34
SLC6A4 P31645 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
CHRNA7 P36544 1/20 0.33
HPGD P15428 1/20 0.33
ATM Q13315 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15943914 0.89 PRKCI (0.45) PRKCIIDO1PRMT5DDB1CRBN
SCHEMBL18731876 0.87 DRD2 (0.42) PRKCIIDO1DDB1CRBNIKZF3
SCHEMBL18787932 0.86 PRKCI (0.50) PRKCIIDO1PRMT5DDB1CRBN
SCHEMBL21025784 0.84 HSD17B10 (0.44) DRD2SLC6A4HPGDATMKMT2A
SCHEMBL15943763 0.84 PRMT5 (0.39) PRKCIIDO1PRMT5KCNH2DRD2
SCHEMBL15943782 0.83 LRRK2 (0.40) PRKCIIDO1PRMT5KCNH2DRD2
SCHEMBL19928081 0.83 PRKCI (0.37) PRKCIIDO1PRMT5WDR77
SCHEMBL15833603 0.81 PRKCI (0.51) PRKCICHRNB2CHRNA4PRMT5WDR77
SCHEMBL15943820 0.81 DRD2 (0.43) PRMT5DRD2SLC6A4KMT2A
SCHEMBL15943817 0.81 DRD2 (0.46) PRMT5DRD2SLC6A4HPGDATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186798-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2018-07-05 US disclosed
US-9908887-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2018-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186798-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRKCI 421/4885IDO1 1784/4885CHRNB2 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.